Camilla Myhre Sandberg

Camilla Myhre Sandberg serves as a Member of the Board at Monivent AB and NextCell Pharma AB, while holding the position of CEO at both Miris Holding AB and Miris AB. With extensive experience in strategic marketing and business development, Camilla previously held significant roles at GE Healthcare Life Sciences, culminating as Strategic Marketing Leader for Cell Technologies. This role involved leading strategic initiatives, enhancing market partnerships, and contributing to business planning processes. Camilla's early career included positions at Dynal Biotech, where responsibilities encompassed global business development and key account management. Camilla holds a Master of Science in Toxicology from the University of Oslo and has pursued education at BI Norwegian Business School and Mid Sweden University.